{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:39:54Z","timestamp":1787013594041,"version":"build-2736575974"},"reference-count":57,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Alopecia areata (AA) is an autoimmune disorder that manifests as nonscarring hair loss and imposes a substantial disease burden. The current study, using an e\u2010claims database, assesses the disease burden, comorbidities, treatment patterns, specialties involved in the diagnosis of AA, healthcare resource utilization (HCRU), and associated costs in privately insured patients with AA in Dubai, United Arab Emirates. The retrospective longitudinal secondary study was conducted using Dubai Real\u2010World Database e\u2010claims data during 01 January 2014 to 30 June 2022. Patients with at least one diagnosis claim of AA during the index period (01 January 2015\u201330 June 2021) with continuous enrollment (one or more AA\/non\u2010AA claim in the post\u2010index period) were included in the analysis. The patients were stratified into subcohorts based on diagnosis code and treatment patterns, as mild,\n                    <jats:bold>moderate\u2010to\u2010severe<\/jats:bold>\n                    , and others. Demographics, comorbidities, treatment patterns, specialists visited, and HCRU were assessed. The study included 11\u2009851 patients with AA (mean age: mild: 37\u2009years;\n                    <jats:bold>moderate\u2010to\u2010severe<\/jats:bold>\n                    : 36\u2009years), with a male predominance (mild: 77.6%;\n                    <jats:bold>moderate\u2010to\u2010severe<\/jats:bold>\n                    : 60.8%). The most prevalent comorbidities in the moderate\u2010to\u2010severe AA subcohort were autoimmune and T\u2010helper 2\u2013mediated immune disorders, including contact dermatitis and eczema (62.1%), atopic dermatitis (36.1%), and asthma (36.1%). Most patients consulted dermatologists for treatment advice (mild AA: 87.4%; moderate\u2010to\u2010severe AA: 47.7%) and, notably, within 1 day of AA diagnosis. Topical steroids were frequently prescribed across cohorts, regardless of disease severity. Analysis of comorbidities among patients with AA indicated an additional HCRU burden among these subsets of patients. The median disease\u2010specific HCRU cost was higher for psychological comorbidities versus autoimmune and T\u2010helper 2\u2013mediated immune disorders (US $224.99 vs US $103.70). There is a substantial disease and economic burden in patients with AA and associated comorbid conditions; therefore, investing in novel therapies that target the underlying autoimmune pathway may address the gap in effective management of AA.\n                  <\/jats:p>","DOI":"10.1111\/1346-8138.17381","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T05:26:41Z","timestamp":1721885201000},"page":"1157-1171","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database"],"prefix":"10.1111","volume":"51","author":[{"given":"Anwar Al","family":"Hammadi","sequence":"first","affiliation":[{"name":"DermaMed Clinic  Dubai UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9732-9993","authenticated-orcid":false,"given":"Nisha V.","family":"Parmar","sequence":"additional","affiliation":[{"name":"DermaMed Clinic  Dubai UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Farghaly","sequence":"additional","affiliation":[{"name":"Dubai Health Authority  Dubai UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Al","family":"Dallal","sequence":"additional","affiliation":[{"name":"Dubai Health Authority  Dubai UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa Wagdy Abdullah","family":"Zayed","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Ltd  Dubai UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadwa","family":"Ebeid","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Ltd  Dubai UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaresan","family":"Subramanyam","sequence":"additional","affiliation":[{"name":"EMEA Consulting Services IQVIA  Bengaluru India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9965-1492","authenticated-orcid":false,"given":"Badarinath Chickballapur","family":"Ramachandrachar","sequence":"additional","affiliation":[{"name":"Real\u2010World Evidence, IQVIA  Dubai UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2883-3317","authenticated-orcid":false,"given":"Haytham Mohamed","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Ltd  Dubai UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-053137"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S331579"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.036"},{"key":"e_1_2_8_5_1","unstructured":"Alopecia areata \u2013 Level 3 cause. The Institute for Health Metrics and Evaluation (IHME). Available from:https:\/\/www.healthdata.org\/results\/gbd_summaries\/2019\/alopecia\u2010areata\u2010level\u20103\u2010cause"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13958"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7194270"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.007"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.013"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16364"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000497166"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2017.07.001"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00512-0"},{"key":"e_1_2_8_14_1","unstructured":"Alopecia areata: diagnosis treatment and steps to take. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Available from:https:\/\/www.niams.nih.gov\/health\u2010topics\/alopecia\u2010areata\/diagnosis\u2010treatment\u2010and\u2010steps\u2010to\u2010take"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01293-0"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.077"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jisp.2020.04.004"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15489"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950450"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.05.027"},{"key":"e_1_2_8_21_1","unstructured":"PF\u201006651600 for the treatment of Alopecia Areata (ALLEGRO\u20102b\/3).clinicaltrial.gov. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03732807?cond=Alopecia+areata&phase=12&draw=2&rank=1"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00222-2"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/983804"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.5218"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.4.426"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01845-0"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00710-4"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2022.36229"},{"key":"e_1_2_8_29_1","volume-title":"National Alopecia Areata Foundation","year":"2024"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-020-02158-y"},{"key":"e_1_2_8_31_1","unstructured":"United Arab Emirates population statistics 2023.2023. Available from:https:\/\/www.globalmediainsight.com\/blog\/uae\u2010population\u2010statistics\/#:~:text=The%20UAE%20Population%20in%202022 in%202022%20is%208.92%20Million"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(09)71118-6"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14507"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20628"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000510880"},{"key":"e_1_2_8_36_1","unstructured":"UAE population and demographics. Available from:https:\/\/www.dubai\u2010online.com\/essential\/uae\u2010population\u2010and\u2010demographics."},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.3049"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13729"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.4398"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jisp.2020.05.007"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21055"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llac104"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2227299"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S309215"},{"key":"e_1_2_8_45_1","unstructured":"US Food and Drug Administration.FDA approves first systemic treatment for alopecia areata 2022. Available from:https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010systemic\u2010treatment\u2010alopecia\u2010areata"},{"key":"e_1_2_8_46_1","unstructured":"FDA approves second Yale\u2010researched treatment for alopecia areata.2023. Available from:https:\/\/news.yale.edu\/2023\/06\/26\/fda\u2010approves\u2010second\u2010yale\u2010researched\u2010treatment\u2010alopecia\u2010areata"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32987-8"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754221130243"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijt.ijt_99_17"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/14764172.2016.1248440"},{"key":"e_1_2_8_52_1","first-page":"156","article-title":"Prevalence of depression in patients with alopecia in Iran: a systematic review and meta\u2010analysis","volume":"8","author":"Mohammadi M","year":"2017","journal-title":"J Dermatol Cosmet"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.25251\/skin.6.6.9"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2188843"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.028"},{"key":"e_1_2_8_56_1","unstructured":"The hidden costs of alopecia areata.2022. Available from:https:\/\/www.healthline.com\/health\/alopecia\u2010areata\u2010financial\u2010costs#treatment"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jisp.2020.05.003"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.4441"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T04:14:25Z","timestamp":1741752865000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.17381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/1346-8138.17381"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.17381","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]},"assertion":[{"value":"2024-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}